NGVT

Rating neutralAI Memo

Ingevity

As of 2026-10-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

November 4 third-quarter results test raised guidance • 2026-11-04

Base target: $74 / p=50% prob

Biggest risk

Reported Q2 sales fell 5%, management called the second-half outlook measured, and some polymer improvement reflected competitor supply disruptions that may fade [#SEC-8K-2026-07-29].

Invalidation

Break below $57 or thesis failure.

What would change my mind?

Q2 sales excluding divested Road Markings rose 5%, adjusted EBITDA rose 14%, and adjusted EBITDA margin expanded to 36.6%; sustained execution could support the raised full-year outlook [#SEC-8K-2026-07-29].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-18

Base target

$74

p=50%

Bull target

$86

p=25%

Bear target

$57

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Test whether margin gains persist
Carbon-filtration commercialization
Q2 sales excluding divested Road Markings rose 5%, adjusted EBITDA rose 14%, and adjusted EBITDA margin expanded to 36.6%; sustained execution could support the raised full-year outlook [#SEC-8K-2026-07-29].

BearKey bullets

Q2 operating cash flow was negative $15.8 million, affected by a $113.2 million litigation settlement payment [#SEC-8K-2026-07-29].
Raised full-year guidance depends on second-half execution despite management's measured outlook [#SEC-8K-2026-07-29].
Raw-material and energy costs required an Advanced Polymer Technologies price surcharge; competitor supply disruptions may prove temporary [#SEC-8K-2026-07-29].

WatchKey bullets

November 4 third-quarter results test raised guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $74 (p=50%)

Target spread vs base: +16% / -23%

Scenario probabilities

Bull Target: $86 (p=25%)Base Target: $74 (p=50%)Bear Target: $57 (p=25%)

Commentary

The Q2 company release supports improving operating performance, but the November print remains the next decisive update. The packet provides no dependable immediate post-release price reaction, current analyst revisions, or target-change series. Sentiment-field zeroes denote unavailable measurements, not neutral readings; recent headline coverage is thin.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Reported Q2 sales fell 5%, management called the second-half outlook measured, and some polymer improvement reflected competitor supply disruptions that may fade [#SEC-8K-2026-07-29].

Drivers

Scannable catalysts and supporting factors

Test whether margin gains persist
Carbon-filtration commercialization

Scenarios

Bull Target (Scenario probability)

$86 / p=25% prob

Base Target (Scenario probability)

$74 / p=50% prob

Bear Target (Scenario probability)

$57 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-04
November 4 third-quarter results test raised guidance
Ingevity scheduled its third-quarter release for November 4 and webcast for November 5 [#PR-EARNINGS-2026-10-07]. After reporting Q2 adjusted EBITDA of $115.0 million, it raised full-year adjusted EBITDA guidance to $380–$400 million while describing its second-half outlook as measured [#8-K-2026-07-29] [#SEC-8K-2026-07-29]. The print should clarify whether that range remains achievable.
Prob 55.00% • Move 8.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Test whether margin gains persist
2026-11-04
Q2 adjusted EBITDA margin rose to 36.6% from 30.5%, supported by price, mix, volumes and utilization. Advanced Polymer Technologies also benefited from competitor supply disruptions, which may not persist [#SEC-8K-2026-07-29]. The next results offer a test of the durability of those gains.
Prob 55% • Move 5% • Priced-in 45%

Long-term Catalysts

Months to a year

Carbon-filtration commercialization
2027-12-31
Management described a municipal PFAS-filtration contract as early commercial validation of its carbon technology [#SEC-8K-2026-07-29]. Further contracts could broaden the opportunity, but disclosed evidence does not establish revenue scale or timing; the date is a monitoring horizon, not a company milestone.
Prob 35% • Move 7% • Priced-in 20%

Risks

Q2 operating cash flow was negative $15.8 million, affected by a $113.2 million litigation settlement payment [#SEC-8K-2026-07-29].
Raised full-year guidance depends on second-half execution despite management's measured outlook [#SEC-8K-2026-07-29].
Raw-material and energy costs required an Advanced Polymer Technologies price surcharge; competitor supply disruptions may prove temporary [#SEC-8K-2026-07-29].
The PFAS-filtration contract has no disclosed revenue scale or commercialization timetable in the available excerpt [#SEC-8K-2026-07-29].

Peers

Symbol	Summary
IOSP	Innospec is an adjacent specialty-chemicals reference, but product mix differs and the packet provides no defensible like-for-like valuation multiple.
KWR	Quaker Houghton appears in the prior baseline as a specialty/process-materials reference. Portfolio and end-market differences make it contextual rather than a direct valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

IOSP

Innospec is an adjacent specialty-chemicals reference, but product mix differs and the packet provides no defensible like-for-like valuation multiple.

KWR

Quaker Houghton appears in the prior baseline as a specialty/process-materials reference. Portfolio and end-market differences make it contextual rather than a direct valuation peer.